ExodusPoint Capital Management LP Raises Holdings in RxSight, Inc. (NASDAQ:RXST)

ExodusPoint Capital Management LP lifted its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 36.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 24,417 shares of the company’s stock after purchasing an additional 6,534 shares during the period. ExodusPoint Capital Management LP’s holdings in RxSight were worth $839,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Quarry LP raised its stake in shares of RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after buying an additional 288 shares in the last quarter. Private Trust Co. NA purchased a new position in shares of RxSight during the 4th quarter worth approximately $34,000. Arcadia Investment Management Corp MI purchased a new position in shares of RxSight during the 4th quarter worth approximately $46,000. Harbor Investment Advisory LLC purchased a new position in shares of RxSight during the 4th quarter worth approximately $52,000. Finally, Global Retirement Partners LLC purchased a new position in shares of RxSight during the 4th quarter worth approximately $69,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Stock Performance

Shares of NASDAQ:RXST opened at $14.19 on Friday. The business’s fifty day moving average price is $26.03 and its two-hundred day moving average price is $36.46. The stock has a market cap of $574.57 million, a PE ratio of -17.10 and a beta of 1.26. RxSight, Inc. has a one year low of $14.02 and a one year high of $66.54.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The business had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.23 million. As a group, equities research analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RXST has been the subject of a number of analyst reports. JPMorgan Chase & Co. reissued an “underweight” rating and set a $17.00 target price (down from $40.00) on shares of RxSight in a research note on Friday, April 4th. Wells Fargo & Company dropped their price objective on RxSight from $35.00 to $22.00 and set an “equal weight” rating for the company in a research note on Thursday, April 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price objective on shares of RxSight in a research note on Thursday, April 3rd. UBS Group downgraded RxSight from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $45.00 to $16.00 in a research note on Wednesday. Finally, Stifel Nicolaus dropped their price objective on RxSight from $33.00 to $28.00 and set a “hold” rating for the company in a research note on Wednesday, March 19th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $39.78.

Insider Transactions at RxSight

In other news, Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the sale, the director now owns 24,793 shares in the company, valued at $637,428.03. This trade represents a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jesse Anderson Corley acquired 1,443 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the acquisition, the director now directly owns 1,443 shares of the company’s stock, valued at approximately $44,992.74. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 9.36% of the company’s stock.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.